{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T21:09:45Z","timestamp":1778101785879,"version":"3.51.4"},"reference-count":36,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>Randomized controlled trials (RCTs) show a reduction in acute kidney injury, renal impairment and acute renal failure after initiation of a sodium glucose cotransporter\u20102 inhibitor. Observational literature on the association is conflicting, but important to understand for populations with a higher risk of medication\u2010related adverse renal events. We aimed to systematically review the literature to summarize the association between sodium glucose cotransporter\u20102 inhibitor use and acute kidney injury, renal impairment and acute renal failure in three at\u2010risk groups: older people aged &gt;65\u2009years, people with heart failure and people with reduced renal function. A systematic search of Embase (1974 until 23 February 2024) and PubMed (1946 until 23 February 2024) was performed. RCTs were included if they reported numbers of acute kidney injury or acute renal failure in people using sodium glucose cotransporter\u20102 inhibitors compared to other diabetic therapies. Studies needed to report results by level of renal function, heart failure status or age. Of 922 results, eight studies were included. The absolute risk of acute kidney injury or acute renal failure was higher in people &gt;65\u2009years compared to those &lt;65\u2009years, higher in people with heart failure (<jats:italic>vs<\/jats:italic> without) and higher in people with reduced kidney function (<jats:italic>vs<\/jats:italic> preserved kidney function), but insufficient evidence to determine if the relative effect of sodium glucose cotransporter\u20102 inhibitors on this risk was similar for each group. At\u2010risk cohorts are associated with a higher incidence of acute kidney problems in users of sodium glucose cotransporter\u20102 inhibitors.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.16088","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T07:58:25Z","timestamp":1716537505000},"page":"1541-1558","source":"Crossref","is-referenced-by-count":6,"title":["Acute kidney injury, renal impairment and renal failure associated with sodium glucose co\u2010transporter\u20102 inhibitors in at\u2010risk groups: A systematic review"],"prefix":"10.1111","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0942-6940","authenticated-orcid":false,"given":"Kate E. D.","family":"Ziser","sequence":"first","affiliation":[{"name":"Centre for Medication Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences Monash University  Parkville VIC Australia"},{"name":"Pharmacy Department Princess Alexandra Hospital  Brisbane QLD Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5337-8061","authenticated-orcid":false,"given":"Adam C.","family":"Livori","sequence":"additional","affiliation":[{"name":"Centre for Medication Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences Monash University  Parkville VIC Australia"},{"name":"Pharmacy Department Grampians Health Ballarat  Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3231-5758","authenticated-orcid":false,"given":"Jedidiah I.","family":"Morton","sequence":"additional","affiliation":[{"name":"Centre for Medication Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences Monash University  Parkville VIC Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7500-8494","authenticated-orcid":false,"given":"Adaire","family":"Prosser","sequence":"additional","affiliation":[{"name":"SA Pharmacy Flinders Medical Centre  Bedford Park SA Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0348-9441","authenticated-orcid":false,"given":"Jenni","family":"Ilom\u00e4ki","sequence":"additional","affiliation":[{"name":"Centre for Medication Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences Monash University  Parkville VIC Australia"},{"name":"School of Public Health and Preventive Medicine Monash University  Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9256-2216","authenticated-orcid":false,"given":"Stephen J.","family":"Wood","sequence":"additional","affiliation":[{"name":"Centre for Medication Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences Monash University  Parkville VIC Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2018.06.1042"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1186"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/1753\u20100407.12616"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2020.1808454"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfu299"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011798.pub2"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13618"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125\u2010018\u20104729\u20105"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv010"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2020.03.019"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4365"},{"key":"e_1_2_10_15_1","unstructured":"Astra Zeneca.Summary of product characteristics [Internet]. Accessed February 3 2021.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/forxiga\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc20\u2010S012"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2016.1219341"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1392293"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13125"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.12881"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001063"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13532"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.191283"},{"key":"e_1_2_10_24_1","unstructured":"ERfR. Cochrane Effective Practice and Organisation of Care (EPOC).Suggested risk of bias assessment for EPOC reviews;2017. Accessed February 3 2021.https:\/\/epoc.cochrane.org\/sites\/epoc.cochrane.org\/files\/public\/uploads\/Resources-for-authors2017\/suggested_risk_of_bias_criteria_for_epoc_reviews.pdf"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14\u20100315"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19\u20101476"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.005875"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1611290"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.028268"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.04.040"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051685"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206286"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14747"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.16088","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T08:49:50Z","timestamp":1719478190000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.16088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1111\/bcp.16088"],"URL":"https:\/\/doi.org\/10.1111\/bcp.16088","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,24]]}}}